Similar articles

• Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?

  Amano K, Takakura K. Amano K, et al. Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):5-18. doi: 10.1159/000099849. Stereotact Funct Neurosurg. 1997. PMID: 9711730 Clinical Trial.
• Treatment of early Parkinson's disease: are complicated strategies justified?

  Ahlskog JE. Ahlskog JE. Mayo Clin Proc. 1996 Jul;71(7):659-70. doi: 10.1016/S0025-6196(11)63004-8. Mayo Clin Proc. 1996. PMID: 8656708 Review.
• Dopamine agonists in the treatment of Parkinson's disease.

  Pahwa R, Koller WC. Pahwa R, et al. Cleve Clin J Med. 1995 Jul-Aug;62(4):212-7. doi: 10.3949/ccjm.62.4.212. Cleve Clin J Med. 1995. PMID: 7641388 Review.
• Pergolide and Parkinson's disease: new preparation. No clear benefit.

  [No authors listed] [No authors listed] Prescrire Int. 2000 Dec;9(50):177-9. Prescrire Int. 2000. PMID: 11475497
• A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease.

  Pezzoli G, Martignoni E, Pacchetti C, Angeleri V, Lamberti P, Muratorio A, Bonuccelli U, De Mari M, Foschi N, Cossutta E, et al. Pezzoli G, et al. Neurology. 1995 Mar;45(3 Suppl 3):S22-7. doi: 10.1212/wnl.45.3_suppl_3.s22. Neurology. 1995. PMID: 7715793 Clinical Trial.